Dr. Cabilly has been a member of the Silenseed board of directors since inception in December 2008. Dr. Cabilly is a scientist and inventor in the field of immunology, whose major breakthrough inventions (the “Cabilly patents”) are related to recombinant antibody production. Dr. Cabilly also served as the co-founder and the Chief Scientist of Ethrog Biotechnology, where he invented dry buffer technologies enabling the production of a disposable apparatus for gel electrophoresis containing no liquid as well as a technology for molecular separation within small zones. In 2001, Ethrog was purchased by Invitrogen (today Thermo Fisher). Dr. Cabilly is a member of the Board of Directors of several private and public high technology companies in Israel, including Neuroderm (NASDAQ:NDRM), RedHill Biopharma (NASDAQ:RDHL), BioCep, Pango, Oplon, Efranat and ViDAC.